JP2015189708A - oral care composition - Google Patents
oral care composition Download PDFInfo
- Publication number
- JP2015189708A JP2015189708A JP2014068015A JP2014068015A JP2015189708A JP 2015189708 A JP2015189708 A JP 2015189708A JP 2014068015 A JP2014068015 A JP 2014068015A JP 2014068015 A JP2014068015 A JP 2014068015A JP 2015189708 A JP2015189708 A JP 2015189708A
- Authority
- JP
- Japan
- Prior art keywords
- green tea
- oral care
- care composition
- liposome
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 239000002502 liposome Substances 0.000 claims abstract description 79
- 235000013824 polyphenols Nutrition 0.000 claims description 60
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 59
- 244000269722 Thea sinensis Species 0.000 claims description 55
- 235000009569 green tea Nutrition 0.000 claims description 50
- 150000003904 phospholipids Chemical class 0.000 claims description 29
- -1 gallate catechins Chemical class 0.000 claims description 26
- 235000005487 catechin Nutrition 0.000 claims description 24
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 24
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 18
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 17
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 15
- 229950001002 cianidanol Drugs 0.000 claims description 15
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 12
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 9
- 150000001765 catechin Chemical class 0.000 claims description 7
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 6
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 6
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 claims description 3
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 claims description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 3
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 claims description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 3
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims description 3
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims description 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 3
- 235000012734 epicatechin Nutrition 0.000 claims description 3
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 abstract description 22
- 239000000725 suspension Substances 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 12
- 210000003296 saliva Anatomy 0.000 abstract description 10
- 230000003993 interaction Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000002688 persistence Effects 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 238000000034 method Methods 0.000 description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 239000008213 purified water Substances 0.000 description 20
- 235000019441 ethanol Nutrition 0.000 description 14
- 239000003205 fragrance Substances 0.000 description 14
- 235000013772 propylene glycol Nutrition 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 11
- 239000004094 surface-active agent Substances 0.000 description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 6
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 229940094952 green tea extract Drugs 0.000 description 6
- 235000020688 green tea extract Nutrition 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 150000005846 sugar alcohols Polymers 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 230000008719 thickening Effects 0.000 description 6
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 5
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical class CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002324 mouth wash Substances 0.000 description 5
- 229940051866 mouthwash Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229940085605 saccharin sodium Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229920003169 water-soluble polymer Polymers 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
- 229940038773 trisodium citrate Drugs 0.000 description 4
- 206010007882 Cellulitis Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229930184207 Polyphenon Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 229940087559 grape seed Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- 208000005888 Periodontal Pocket Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 2
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 244000191502 Chenopodium murale Species 0.000 description 1
- 235000000751 Chenopodium murale Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 206010044016 Tooth abscess Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229960000414 sodium fluoride Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は、緑茶ポリフェノールを含有するリポソーム分散液からなるオーラルケア組成物に関する。 The present invention relates to an oral care composition comprising a liposome dispersion containing green tea polyphenol.
日本のみならず多くの国において、人口構成に占める高齢者の割合が増加しており、それに伴い如何に高いQOLを維持するかが重要視されつつある。その手段の一つに口腔ケアが重要であることが最近の研究で明らかになりつつある。具体的には、口腔内細菌が口腔内の感染症等だけでなく細菌性心内膜炎、不顕性肺炎、糸球体腎炎、関節炎などといった全身の疾患の原因になりうることが知られつつある。一方、口腔内細菌は、年齢との関連性があることが知られており、高齢者においては通常口腔内には常在しない黄色ブドウ球菌、緑膿菌などのいわゆる日和見感染菌と称される細菌も常在する比率が高くなる傾向にある。特に、黄色ブドウ球菌は、頬部蜂窩織炎や口底蜂窩織炎などの蜂窩織炎、顎骨骨髄炎、インプラント埋入後の歯周炎や歯根膿瘍といった口腔領域の疾患だけでなく、誤嚥性肺炎を惹起する原因となることから、黄色ブドウ球菌の制御は高齢者における口腔内ケアにおいて重要な要素と考えられている。 In many countries as well as in Japan, the proportion of elderly people in the population structure is increasing, and accordingly, how to maintain a high QOL is being emphasized. Recent studies are revealing the importance of oral care as one of the means. Specifically, it is known that oral bacteria can cause systemic diseases such as bacterial endocarditis, subclinical pneumonia, glomerulonephritis, arthritis as well as infections in the oral cavity. is there. On the other hand, oral bacteria are known to be related to age, and are called so-called opportunistic bacteria such as Staphylococcus aureus and Pseudomonas aeruginosa that are not normally present in the oral cavity in the elderly. Bacteria tend to be present at higher rates. In particular, Staphylococcus aureus is not only used for oral diseases such as cellulitis such as cheek cellulitis and cellulitis, jaw osteomyelitis, periodontitis after implant placement, and root abscess, but also aspiration. Control of Staphylococcus aureus is considered to be an important element in oral care in the elderly because it causes pneumonia.
口腔内において多くの細菌は、口腔内に浮遊しているかバイオフィルムと呼ばれる細菌の凝集体に存在している。浮遊している細菌の除去は容易であるが、バイオフィルムは物理的な作用にも化学的な作用にも耐性を有しており、バイオフィルムを除去することは強力な作用を有する方法を用いないと困難である。たとえば、専門的機械歯面清掃(PMTC)+3DSという化学的作用と物理的作用を活用した除去方法が実施されている。この方法は、通常、専用の剥離・洗浄用の組成物を強い機械力を用いて口腔内を清掃することでバイオフィルムを除去したのちに残存する細菌を殺菌剤含有組成物の使用により排除する方法である。しかしこの方法は、高齢者や口腔組織に異常を有する人のようないわゆる口腔弱者においては、物理的、化学的な刺激が強すぎるため諸問題を引き起こす可能性があるため好ましくない。また、歯間部や歯周ポケットなどの峡間部位においては、当該部位の清掃後に使用してもオーラルケア組成物が到達しにくかったり、到達しても効果を発揮するに十分な有効成分の量を滞留できないことが多く、これら口腔内の峡間部位の口腔衛生状態が悪化し易い課題点が存在する。 Many bacteria in the oral cavity are present in bacterial aggregates floating in the oral cavity or called biofilms. Although it is easy to remove floating bacteria, biofilms are resistant to both physical and chemical effects, and removing biofilms uses a powerful method. If not, it will be difficult. For example, a special mechanical tooth surface cleaning (PMTC) + 3DS removal method utilizing a chemical action and a physical action has been implemented. This method usually eliminates bacteria remaining after removing the biofilm by cleaning the inside of the oral cavity with a strong mechanical force using a dedicated exfoliating / cleaning composition by using a disinfectant-containing composition. Is the method. However, this method is not preferable for so-called weak oral persons, such as elderly people and persons having abnormalities in oral tissues, because it may cause various problems because the physical and chemical stimuli are too strong. In addition, in the inter-oral regions such as interdental parts and periodontal pockets, the oral care composition is difficult to reach even after being used after cleaning the region, or the amount of the active ingredient sufficient to exert the effect even if it reaches. In many cases, the oral hygiene state of the inter-oral region in the oral cavity tends to deteriorate.
一方、オーラルケア組成物を口腔内に滞留させるための技術開発が数多く行われている。例えば、高分子成分を配合する方法(特許文献1〜7)、特定の非イオン性界面活性剤を配合する方法(特許文献8,9)、高分子担体に共有結合させることで滞留性を高める方法(特許文献10)および唾液成分中のカルシウムにより組成物を増粘させる水溶性高分子を配合することで適用部位における薬用成分の滞留性と作用の持続性を向上させる方法(特許文献11、12)が挙げられる。しかし、高分子を配合して組成物の粘度を高める方法では、口腔内の峡間部位への組成物の到達が十分に行えないため、前記課題の解決は困難であり、特定の非イオン性界面活性剤を配合する方法では、峡間部位に組成物が到達しても当該部位に残留する組成物量が少ないため、十分な効果を見込めない、さらには唾液中のカルシウム成分と反応を起こし増粘する高分子を配合する技術では、峡間部位に到達し易くかつ当該部位で残留する組成物量を十分に確保できる可能性はあるが、薬効成分の効果の持続性が十分でない課題点があった。 On the other hand, many technical developments for retaining an oral care composition in the oral cavity have been conducted. For example, a method of blending a polymer component (Patent Documents 1 to 7), a method of blending a specific nonionic surfactant (Patent Documents 8 and 9), and increasing the retention by covalent bonding to a polymer carrier Method (Patent Document 10) and a method for improving the retention of the medicinal component at the application site and the sustainability of the action by blending a water-soluble polymer that thickens the composition with calcium in the saliva component (Patent Document 11, 12). However, in the method of increasing the viscosity of the composition by adding a polymer, it is difficult to solve the above problem because the composition cannot sufficiently reach the intraoral site in the oral cavity, and a specific nonionic interface In the method of blending the active agent, even if the composition reaches the canyon site, the amount of the composition remaining in the site is small, so a sufficient effect cannot be expected, and further, it reacts with the calcium component in saliva and thickens In the technique of blending the polymer, there is a possibility that the amount of the composition that can easily reach the canyon site and remain at the site can be sufficiently secured, but there is a problem that the sustainability of the effect of the medicinal component is not sufficient.
唾液成分と相互作用を有するリポソーム懸濁液を用いることにより、口腔内に適用する時は組成物の粘度が十分に低いために口腔内の峡間部位に十分に到達でき、唾液成分と相互作用を起こして組成物の粘度が高くなるので、到達した峡間部位において十分な量の組成物を残留させることができ、かつリポソームに有用成分を包含させることにより有用成分の効果を持続的に発揮させることが可能し、高い安全性も有するため、高い口腔衛生ケアを実現させることのできる口腔弱者に対しても使用可能なオーラルケア組成物を提供することを目的とする。 By using a liposome suspension that interacts with saliva components, the composition has a sufficiently low viscosity when applied to the oral cavity, so that it can reach the interoral site in the oral cavity and interact with the saliva components. Since the viscosity of the composition is increased, a sufficient amount of the composition can be left in the reached canyon site, and the useful component can be continuously exerted by including the useful component in the liposome. Therefore, an object of the present invention is to provide an oral care composition that can be used even for the vulnerable oral cavity who can realize high oral hygiene care.
本発明者らは、かかる事情に鑑み鋭意検討を重ねた結果、驚くべきことに緑茶ポリフェノールをリポソームに包含させて得られるリポソーム分散液を口腔に適用すると、唾液成分との相互作用により組成部の粘度が大幅に増大することを見出し、本発明を完成するに至った。 As a result of intensive studies in view of such circumstances, the present inventors surprisingly applied a liposome dispersion obtained by including green tea polyphenol in liposomes to the oral cavity, and the interaction between the composition and the saliva component resulted in The present inventors have found that the viscosity is greatly increased and have completed the present invention.
すなわち、本発明は、項1ないし項4のオーラルケア組成物を提供するものである。
項1.
緑茶ポリフェノールと水素添加処理したリン脂質を含有するリポソームの分散水溶液からなるオーラルケア組成物。
項2.
水素添加処理したリン脂質中のホスファチジルコリン含量が質量比で50%以上であることを特徴とする項1に記載のオーラルケア組成物。
項3.
水素添加処理したリン脂質中のホスファチジルコリン含量が質量比で50%〜90%であることを特徴とする項2に記載のオーラルケア組成物。
項4.
緑茶ポリフェノールが、カテキン、エピカテキン、ガロカテキン、エピガロカテキンからなるカテキン類、及びカテキンガレート、エピカテキンガレート、ガロカテキンガレート、エピガロカテキンガレートからなるガレートカテキン類から選ばれる1種以上のポリフェノールを、緑茶ポリフェノール全量に対して乾燥物換算で30質量%以上含有することを特徴とする項1または2の何れか1項に記載のオーラルケア組成物。
項5.
リポソームが油脂を含有することを特徴とする項1、2または4の何れか1項に記載のオーラルケア組成物。
That is, this invention provides the oral care composition of claim | item 1 thru | or claim | item 4.
Item 1.
An oral care composition comprising an aqueous dispersion of liposomes containing green tea polyphenols and hydrogenated phospholipids.
Item 2.
Item 2. The oral care composition according to Item 1, wherein the phosphatidylcholine content in the hydrogenated phospholipid is 50% or more by mass ratio.
Item 3.
Item 3. The oral care composition according to Item 2, wherein the phosphatidylcholine content in the hydrogenated phospholipid is 50% to 90% by mass.
Item 4.
The green tea polyphenol is one or more polyphenols selected from catechins consisting of catechin, epicatechin, gallocatechin, epigallocatechin, and gallate catechins consisting of catechin gallate, epicatechin gallate, gallocatechin gallate, epigallocatechin gallate, Item 3. The oral care composition according to any one of Items 1 or 2, wherein the oral care composition contains 30% by mass or more in terms of dry matter with respect to the total amount of green tea polyphenol.
Item 5.
Item 5. The oral care composition according to any one of Items 1, 2, or 4, wherein the liposome contains an oil or fat.
本発明によれば、口腔内の歯間部や歯周ポケットなどの峡間部位においても十分に組成物が到達し、該部位において効果を発揮するに十分な量を残留でき、且つ、残留後の効果が持続するオーラルケア組成物を提供できる。特に、比較的刺激性が高い場合が多い有用成分をリポソームに包含させており、経時で少しずつ有用成分がリポソームから放出されることから、口腔内組織が化学的な刺激に過敏になっている、いわゆる「口腔弱者」と称される重度の歯周疾患、口腔乾燥症や口腔内の悪性腫瘍を患っている病人、高齢者、乳幼児、被介護者などであっても安心して毎日使用できるため、口腔衛生状態が極めて悪くなりやすい人にも有用なオーラルケア組成物を提供できる。 According to the present invention, the composition can be sufficiently reached even in the inter-orbital region such as the interdental portion and periodontal pocket in the oral cavity, and a sufficient amount can be left to exert the effect in the region. An oral care composition with sustained effects can be provided. In particular, the liposome contains useful ingredients that are often relatively irritating, and the useful ingredients are gradually released from the liposomes over time, making oral tissues sensitive to chemical irritation. Because it can be used every day with peace of mind even for patients with severe periodontal disease called so-called “orally vulnerable”, xerostomia and malignant tumors in the oral cavity, elderly people, infants, cared persons, etc. It is possible to provide an oral care composition that is useful even for people who are extremely prone to poor oral hygiene.
本発明で使用する緑茶ポリフェノールは、ツバキ科ツバキ属の永年性の常緑樹カメリア・シネンシス(Camellia sinensis (L.) O.kuntze)の葉部を、水および/またはエチルアルコール、好ましくは、水-エチルアルコール混液を用いて抽出し、得られるポリフェノールをいい、本発明で用いる緑茶ポリフェノールは、乾燥状態で30質量%以上の緑茶ポリフェノールを含有する粉体若しくは顆粒体を意味する。ポリフェノール含有量は高いほうが好ましく、また、緑茶ポリフェノールにおいても、カテキン、エピカテキン、ガロカテキン、エピガロカテキンからなるカテキン類、及びカテキンガレート、エピカテキンガレート、ガロカテキンガレート、エピガロカテキンガレートからなるガレートカテキン類(以下「EGCG」と略することがある。)から選ばれる1種以上のポリフェノールが好ましく、カテキン類およびEGCGを合わせたポリフェノール(以下、「総カテキン」と略することがある。)の含有量が乾燥状態で30質量%以上のものがさらに好ましく使用できる。緑茶ポリフェノールは、例えば(以下の括弧書きの「%」は乾燥重量あたりの含有量(質量%)を意味する。また、括弧書きの最後には抽出溶媒名を記載する。)、「緑茶ポリフェノールEGCG50」(メディエンス(株)社製、緑茶ポリフェノール(98%以上)、EGCG(45%以上)、総カテキン(75%以上)、水-エチルアルコール混液)、「カテキン30」(白井松新薬(株)社製、緑茶ポリフェノール(30%以上)、EGCG(10%以上)、水)、「カテキン40」(白井松新薬(株)社製、緑茶ポリフェノール(40%以上)、EGCG(10%以上)、水-エチルアルコール混液)、「ポリフェノンG」(三井農林(株)社製、総カテキン(30%以上)、水)、「ポリフェノン70A」(三井農林(株)社製、総カテキン(80%以上)、水-エチルアルコール混液)、「GREEN TEA PE」(ピーエイチエヌ(株)社製、緑茶ポリフェノール(98%以上)、EGCG(50%以上)、総カテキン(80%以上))、「ティアカロン30」((株)常磐植物研究所社製、緑茶ポリフェノール(30%以上)、EGCG(10%以上)、水)、「ティアカロン90」((株)常磐植物研究所社製、緑茶ポリフェノール(90%以上)、EGCG(35%以上))、「ティアカロン90S」((株)常磐植物研究所社製、緑茶ポリフェノール(95%以上)、EGCG(40%以上))、「PF−TP80」((株)ファーマフーズ社製、緑茶ポリフェノール(80%以上)、総カテキン(70%以上))、「PF−TP90」((株)ファーマフーズ社製、緑茶ポリフェノール(90%以上)、総カテキン(80%以上))、「ピュアフェノン50W」(小川香料(株)社製、緑茶ポリフェノール(50%以上)、EGCG(20%以上))、「サンフェノン30S−OP」(太陽化学(株)社製、緑茶ポリフェノール(30%以上)、総カテキン(20%以上))、「サンフェノンCT−T−OP」(太陽化学(株)社製、緑茶ポリフェノール(50%以上))、「サンフェノンBG−3」(太陽化学(株)社製、緑茶ポリフェノール(80%以上)、総カテキン(70%以上))、「サンフェノンBG−5」(太陽化学(株)社製、緑茶ポリフェノール(80%以上)、総カテキン(60%以上))、「サンフェノン90S」(太陽化学(株)社製、緑茶ポリフェノール(80%以上)、総カテキン(70%以上))、「サンフェノンEGCG−OP」(太陽化学(株)社製、EGCG(90%以上))として入手することが可能である。 The green tea polyphenol used in the present invention comprises leaves of perennial evergreen Camellia sinensis (L.) O. kuntze of Camellia camellia, water and / or ethyl alcohol, preferably water-ethyl. It refers to the polyphenol obtained by extraction using an alcohol mixture, and the green tea polyphenol used in the present invention means a powder or granule containing 30% by mass or more of green tea polyphenol in a dry state. Higher polyphenol content is preferred, and also in green tea polyphenols, catechins consisting of catechin, epicatechin, gallocatechin, epigallocatechin, and gallate catechin consisting of catechin gallate, epicatechin gallate, gallocatechin gallate, epigallocatechin gallate One or more polyphenols selected from the group (hereinafter sometimes abbreviated as “EGCG”) are preferred, and the content of catechins and polyphenols combined with EGCG (hereinafter sometimes abbreviated as “total catechins”) is included. More preferably, the amount is 30% by mass or more in a dry state. The green tea polyphenol is, for example (the following “%” in parentheses means the content (% by mass) per dry weight. The name of the extraction solvent is described at the end of the parentheses), “Green tea polyphenol EGCG50 (Made by Medience Co., Ltd., green tea polyphenol (98% or more), EGCG (45% or more), total catechin (75% or more), water-ethyl alcohol mixture), "catechin 30" (Shiraimatsu Shinyaku Co., Ltd.) Manufactured by the company, green tea polyphenols (30% or more), EGCG (10% or more), water), "catechin 40" (manufactured by Shiraimatsu Shinyaku Co., Ltd., green tea polyphenols (40% or more), EGCG (10% or more), Water-ethyl alcohol mixture), “Polyphenone G” (Mitsui Norin Co., Ltd., total catechin (30% or more), water), “Polyphenon 70A” (Mitsui Norin Co., Ltd., total TEKIN (80% or more), water-ethyl alcohol mixture), “GREEN TEA PE” (PHI Corporation), green tea polyphenol (98% or more), EGCG (50% or more), total catechin (80% or more) ), “Tiacalon 30” (manufactured by Joban Plant Research Institute, Inc., green tea polyphenol (over 30%), EGCG (over 10%), water), “Teacalon 90” (manufactured by Joban Plant Research Institute, Ltd., Green tea polyphenols (90% or more), EGCG (35% or more)), “Teacalon 90S” (manufactured by Joban Plant Research Institute, Inc., green tea polyphenols (95% or more), EGCG (40% or more)), “PF- TP80 "(manufactured by Pharma Foods Co., Ltd., green tea polyphenols (80% or more), total catechin (70% or more))," PF-TP90 "(Pharmacies) Manufactured by Co., Ltd., green tea polyphenol (90% or more), total catechin (80% or more), “Purephenon 50W” (manufactured by Ogawa Fragrance Co., Ltd., green tea polyphenol (50% or more), EGCG (20% or more)), “Sanphenon 30S-OP” (manufactured by Taiyo Kagaku Co., Ltd., green tea polyphenol (30% or more), total catechin (20% or more)), “Sunphenon CT-T-OP” (manufactured by Taiyo Kagaku Co., Ltd., green tea Polyphenol (50% or more)), “Sunphenon BG-3” (manufactured by Taiyo Kagaku Co., Ltd., green tea polyphenol (80% or more), total catechin (70% or more)), “Sunphenon BG-5” (Taiyo Chemical ( Co., Ltd., green tea polyphenol (80% or more), total catechin (60% or more)), "Sunphenon 90S" (manufactured by Taiyo Kagaku Co., Ltd., green tea polyphenol (80% or more)) Total catechins (70% or more)), "Sanfenon EGCG-OP" (Taiyo Kagaku Co., Ltd., it is possible to obtain as EGCG (90% or higher)).
緑茶ポリフェノールは、実質的にリポソームに包含された状態で存在させる。ここにおいて、「包含された状態」とは、少なくともリン脂質及び緑茶ポリフェノールを用いてリポソームを調製し、得られたリポソームにおける緑茶ポリフェノールの存在状態を意味し、例えば、緑茶ポリフェノールがリポソーム表面に吸着している状態、リポソームの膜成分の一つとして存在している状態、あるいはリポソームの脂質膜で形成されるリポソーム内の連続層中に存在する状態である。 Green tea polyphenols are present in a state substantially contained in liposomes. Here, the “included state” means a state in which the liposome is prepared using at least phospholipid and green tea polyphenol, and the green tea polyphenol is present in the obtained liposome. For example, the green tea polyphenol is adsorbed on the liposome surface. A state of being present as one of the membrane components of the liposome, or a state of being present in a continuous layer in the liposome formed by the lipid membrane of the liposome.
本発明のリポソームは、少なくとも水素添加処理したリン脂質も含有する。水素添加処理した水素添加リン脂質としては、水素添加グリセロリン脂質、水素添加ホスファチジルエタノールアミン、水素添加ホスファチジルセリン、水素添加ホスファチジルイノシトール、水素添加ホスファチジルコリン(水素添加レシチン:水素添加大豆レシチン、水素添加卵黄レシチン、水素添加コーンレシチン、水素添加綿実油レシチンなど)などが例示できる。このうち、水素添加ホスファチジルコリン(水素添加レシチン:水素添加大豆レシチン、水素添加卵黄レシチン、水素添加コーンレシチン、水素添加綿実油レシチンなど))が好ましい。通常商業ベースで本発明を実施する場合は、ホスファチジルコリン含有量が60質量%以上である水素添加リン脂質(例:水素添加大豆レシチン、水素添加卵黄レシチンなど)を使用でき、70質量%以上のものが好適に使用でき、80質量%以上のものがより好適に使用でき、90質量%以上のものがより好適に使用できる。 The liposome of the present invention also contains at least a hydrogenated phospholipid. Examples of hydrogenated phospholipids include hydrogenated glycerophospholipid, hydrogenated phosphatidylethanolamine, hydrogenated phosphatidylserine, hydrogenated phosphatidylinositol, hydrogenated phosphatidylcholine (hydrogenated lecithin: hydrogenated soybean lecithin, hydrogenated egg yolk lecithin, Examples thereof include hydrogenated corn lecithin, hydrogenated cottonseed oil lecithin and the like. Among these, hydrogenated phosphatidylcholine (hydrogenated lecithin: hydrogenated soybean lecithin, hydrogenated egg yolk lecithin, hydrogenated corn lecithin, hydrogenated cottonseed oil lecithin, etc.)) is preferable. Usually, when the present invention is carried out on a commercial basis, hydrogenated phospholipids (eg, hydrogenated soybean lecithin, hydrogenated egg yolk lecithin, etc.) having a phosphatidylcholine content of 60% by mass or more can be used. Can be preferably used, those having 80% by mass or more can be more preferably used, and those having 90% by mass or more can be more preferably used.
本願における「リポソーム」とは、リン脂質が自己組織化によって形成した単層、または複数の層からなる脂質複合体であり、脂質二重層の数に基づいて、多重膜リポソーム(MLV)と一枚膜リポソームの2つに分類される。一枚膜リポソームは、そのサイズに応じて、更にSUV(small unilamella vesicle)、LUV(large unilamella vesicle)、GUV(giant unilamella vesicle)などに分類され、これらのいずれも好適に使用できる。本発明で好適に用いることのできるリポソームの大きさは、平均粒子径、若しくは該球状の粒子形状をしていない場合は平均外径として10〜1000nmであり、好ましくは10〜600nm、より好ましくは20〜300nmである。リポソームの平均粒子径もしくは平均外径(以下、「平均粒子系等」と略することがある。)は前記の範囲において適宜設定できるが、安定性の観点からはリポソームの粒子系等のバラつきが少ない方が好ましく、平均粒子径等の上限値と下限値の差が1000nm以内、好ましくは300nm以内の範囲に、60%以上のリポソーム個体数(全てのリポソーム数の合計値を100とした時の存在比率を意味する。)、好ましくは80%以上のリポソーム個体数が含まれるのがよい。平均粒子径やリポソーム個体数は、市販の粒度分布計や粒子計数計などで測定することができる。 The “liposome” in the present application is a lipid complex composed of a monolayer or a plurality of layers formed by self-assembly of phospholipids, and one multilamellar liposome (MLV) based on the number of lipid bilayers. There are two types of membrane liposomes. Single-membrane liposomes are further classified into SUV (small unilamella vesicle), LUV (large unilamella vesicle), GUV (giant unilamella vesicle), etc., and any of these can be used preferably. The size of the liposome that can be suitably used in the present invention is 10 to 1000 nm, preferably 10 to 600 nm, more preferably 10 to 600 nm as an average outer diameter when the average particle diameter or the spherical particle shape is not used. 20-300 nm. The average particle diameter or the average outer diameter of the liposome (hereinafter, sometimes abbreviated as “average particle system etc.”) can be set as appropriate within the above range, but from the viewpoint of stability, the liposome particle system may vary. The smaller one is preferable, and the difference between the upper limit value and the lower limit value of the average particle diameter and the like is within 1000 nm, preferably within 300 nm, and the number of liposome individuals of 60% or more (when the total value of all liposome numbers is 100) Means an abundance ratio), and preferably contains 80% or more of the liposome population. The average particle diameter and the number of liposomes can be measured with a commercially available particle size distribution meter or particle counter.
本発明に使用するリポソームは、常法により製造することができる。例えば、リポソーム懸濁液の製造方法としては、(1)リン脂質、リポソームに内包する成分、その他酸化防止剤などを均質に混合した後、pH調整剤、多価アルコール、糖類などを含む水溶液で水和し、リポソームを形成させる方法。(2)リン脂質、リポソームに内包する成分、その他酸化防止剤などをアルコール、多価アルコールなどに溶解し、pH調整剤、多価アルコール、糖類などを含む水溶液で水和し、リポソームを調製する方法。(3)超音波、フレンチプレスやホモジナイザーを用いて、リン脂質、リポソームに内包する成分、その他酸化防止剤などを水中で複合化させ、リポソームを調製する方法。(4)エタノールにリン脂質、リポソームに内包する成分、その他酸化防止剤などを混合溶解し、このエタノール溶液を塩化カリウム水溶液に添加した後にエタノールを除去しリポソームを調製する方法などが利用できる。例えば、所定量の水素添加処理したリン脂質を含むリン脂質を、例えばエタノールなどの適当な有機溶媒で可溶化し、減圧下に溶媒を除去し、膜脂質を作成し、水、緩衝液、糖類含有水溶液などを添加後、例えば、1000〜3000rpm程度で2〜5分間程度撹拌して、リポソーム懸濁液を調製することにより得ることができる。また、水、緩衝液、糖類含有水溶液に、例えばエタノールに溶解した所定量の前記リン脂質を添加し高圧ホモジナイザーなどにより撹拌することによっても調製することができる。リポソームには、イソプロピルメチルフェノールのようなフェノール系殺菌剤だけでなく、適宜、油性成分、脂質、水溶性物質、生理活性物質など、たとえば、トコフェロール、アスコルビン酸などの抗酸化剤、乳酸、クエン酸などの有機酸、ホスファチジルグリセロール、ホスファチジルエタノールアミンなどの脂質、キトサン、フコイダン、ヒアルロン酸などの天然高分子、ポリエチレングリコール、カルボキシビニルポリマーなどの合成高分子、トレハロース、ラクチュロース、マルチトールなどの糖質、グリセリンなどのポリオールなどを、本発明の効果を損なわない範囲で包含させて製剤化することができる。なお、ここでいう「包含」とは、上記に示した通り、リン脂質等の他のリポソーム構成成分と該成分がリポソームを形成していることを意味し、リポソームの内部に構成される親水領域若しくは疎水領域に存在する場合、リポソームの膜構成物質と共存する場合、若しくは、リポソーム構成体の最外膜の膜表面に付着して存在する場合など、種々の存在形態ものが含まれる。通常リポソームは、水などの水性溶媒を連続層として有するリポソーム懸濁液として調製される。得られたリポソーム懸濁液は、そのまま使用してもよいし、凍結乾燥やスプレードライなどの常法を用いて乾燥された形態で使用することもでき、水を含有しない水性溶媒を連続層として有する形態で使用することができる。 The liposome used in the present invention can be produced by a conventional method. For example, as a method for producing a liposome suspension, (1) an aqueous solution containing a pH adjuster, a polyhydric alcohol, a saccharide, etc., after homogeneously mixing phospholipids, components encapsulated in liposomes, and other antioxidants. A method of hydration to form liposomes. (2) Phospholipids, components encapsulated in liposomes, and other antioxidants are dissolved in alcohol, polyhydric alcohol, etc., and hydrated with an aqueous solution containing a pH adjuster, polyhydric alcohol, saccharide, etc. to prepare liposomes. Method. (3) A method of preparing liposomes by complexing phospholipids, components encapsulated in liposomes, other antioxidants and the like in water using ultrasonic waves, a French press or a homogenizer. (4) A method of preparing liposomes by mixing and dissolving phospholipids, components encapsulated in liposomes and other antioxidants in ethanol, adding this ethanol solution to an aqueous potassium chloride solution, and preparing liposomes can be used. For example, a phospholipid containing a predetermined amount of hydrogenated phospholipid is solubilized with an appropriate organic solvent such as ethanol, and the solvent is removed under reduced pressure to create a membrane lipid, which is water, buffer solution, saccharide After adding the aqueous solution, etc., it can be obtained by, for example, stirring at about 1000 to 3000 rpm for about 2 to 5 minutes to prepare a liposome suspension. It can also be prepared by adding a predetermined amount of the phospholipid dissolved in, for example, ethanol to water, a buffer solution, or a saccharide-containing aqueous solution and stirring with a high-pressure homogenizer or the like. Liposomes include not only phenolic fungicides such as isopropylmethylphenol, but also oily ingredients, lipids, water-soluble substances, physiologically active substances, etc., for example, antioxidants such as tocopherol and ascorbic acid, lactic acid, citric acid, etc. Organic acids such as, lipids such as phosphatidylglycerol, phosphatidylethanolamine, natural polymers such as chitosan, fucoidan, hyaluronic acid, synthetic polymers such as polyethylene glycol, carboxyvinyl polymer, carbohydrates such as trehalose, lactulose, maltitol, A polyol such as glycerin or the like can be formulated by including it in a range not impairing the effects of the present invention. As used herein, “inclusion” means that other liposome constituents such as phospholipids and the constituents form liposomes, as shown above, and a hydrophilic region formed inside the liposome. Alternatively, it exists in a hydrophobic region, in a case where it coexists with a membrane constituent material of the liposome, or in a case where it is attached to the outermost membrane surface of the liposome constituent and includes various existing forms. Usually, liposomes are prepared as a liposome suspension having an aqueous solvent such as water as a continuous layer. The obtained liposome suspension may be used as it is, or may be used in a dried form using a conventional method such as freeze-drying or spray-drying, and an aqueous solvent containing no water is used as a continuous layer. It can be used in the form of having.
リポソームに包含されている緑茶ポリフェノールの確認は常法を用いて行なうことができる。すなわち、リポソームに包含せずリポソームを懸濁している連続層に存在する緑茶ポリフェノールを、常法を用いて除去し、その後、常法を用いてリポソーム破壊し、破壊後に遊離する緑茶ポリフェノールの存在を調べることで、リポソームに包含されている緑茶ポリフェノールの確認を行なうことができる。また、同様な手法を用いて定量することも可能である。塩緑茶ポリフェノールの確認や定量の方法としては、限定するものではないが、例えば、HPLCを用いた方法(例えば液体クロマトグラフ質量分析計)が挙げられる。また、リポソームに包含せずリポソームを懸濁している連続層に存在する緑茶ポリフェノールを除去する方法としては、例えば、透析膜等を用いた透析処理や「遠心分離して上澄を除去した後に等張液で残渣物を洗浄し、再度上澄を除去する」操作を繰り返し行なう遠心分離を用いた方法、ゲルろ過処理を行なう方法などが挙げられる。リポソーム破壊する方法としては、例えば、クロロホルムなどの有機溶媒やノニオン性又はカチオン性の界面活性剤を添加する方法が挙げられる。 Confirmation of the green tea polyphenol contained in the liposome can be performed using a conventional method. That is, the green tea polyphenol present in the continuous layer in which the liposome is suspended but not included in the liposome is removed using a conventional method, and then the liposome is disrupted using a conventional method. By examining, green tea polyphenol contained in the liposome can be confirmed. It is also possible to quantify using a similar method. A method for confirming or quantifying the salt green tea polyphenol is not limited, and examples thereof include a method using HPLC (for example, a liquid chromatograph mass spectrometer). In addition, as a method for removing green tea polyphenol present in the continuous layer in which the liposome is suspended without being included in the liposome, for example, a dialysis treatment using a dialysis membrane or the like “after removing the supernatant by centrifugation, etc. Examples include a method using centrifugation in which the residue is washed again with a tonic solution and the supernatant is removed again, and a method of performing gel filtration. Examples of the method for destroying the liposome include a method of adding an organic solvent such as chloroform and a nonionic or cationic surfactant.
本発明のオーラルケア組成物には、多価アルコールを配合させることが好ましい。多価アルコールとしては、プロピレングリコール、1,3−ブチレングリコール、イソプレングリコール、1,2−プロパンジオール、1,3−プロパンジオール、ジプロピレングリコール、ポリエチレングリコール、グリセリン、ソルビトールなどが挙げられる。配合量は、組成物全量に対して1〜20質量%とすることができる。 It is preferable to add a polyhydric alcohol to the oral care composition of the present invention. Examples of the polyhydric alcohol include propylene glycol, 1,3-butylene glycol, isoprene glycol, 1,2-propanediol, 1,3-propanediol, dipropylene glycol, polyethylene glycol, glycerin, sorbitol and the like. A compounding quantity can be 1-20 mass% with respect to the composition whole quantity.
本発明のオーラルケア組成物は、リポソームが水系溶媒に分散している溶液であり、組成物の粘度は、口腔内組織の隅々にまで十分に到達し易くするため、低いほど良く、例えば50mPa・s以下とすることができ、中でも30mPa・s以下が好ましく、20mPa・s以下がより好ましく、10mPa・s以下が最も好ましい。組成物の粘度の測定は、E型回転式粘度計を用い、常法(例えば、JIS Z8803:2011:「10.円すい−平板形回転粘度計による粘度測定方法」)に従って測定する。 The oral care composition of the present invention is a solution in which liposomes are dispersed in an aqueous solvent, and the viscosity of the composition is preferably as low as possible in order to easily reach every corner of the oral tissue, for example, 50 mPa. S or less, among which 30 mPa · s or less is preferable, 20 mPa · s or less is more preferable, and 10 mPa · s or less is most preferable. The viscosity of the composition is measured using an E-type rotary viscometer in accordance with a conventional method (for example, JIS Z8803: 2011 “10. Cones-viscosity measurement method using a flat plate rotational viscometer”).
本発明のオーラルケア組成物は、歯磨剤、洗口剤、口腔乾燥緩和・防止剤、口腔・咽喉殺菌剤、口腔用消炎剤、口臭予防/解消剤、プラーク形成阻止剤、齲蝕防止剤、歯周病予防剤、歯周病治療剤、舌苔除去剤、舌苔形成予防剤、義歯装着剤、義歯コーティング剤、義歯安定化剤、義歯保存剤、義歯洗浄剤、インプラントケア剤などの通常のオーラルケア製品、医薬部外品、医薬品などとして利用することができる。 The oral care composition of the present invention is a dentifrice, mouthwash, mouth dryness relieving / preventing agent, oral cavity / throat disinfectant, oral anti-inflammatory agent, halitosis prevention / elimination agent, plaque formation inhibitor, caries inhibitor, tooth Oral care such as periodontal disease prevention agent, periodontal disease treatment agent, tongue coating remover, tongue coating formation prevention agent, denture mounting agent, denture coating agent, denture stabilizer, denture preservative, denture cleaning agent, implant care agent, etc. It can be used as a product, quasi-drug, pharmaceutical product, etc.
本発明のオーラルケア組成物は、本願効果を損なわない範囲であれば、緑茶ポリフェノールおよびリン脂質以外の一般的に食品やオーラルケア組成物、医薬品等で用いられる公知の成分を配合することができる。たとえば、界面活性剤、アルコール類、水溶性高分子、香味剤(香料)、甘味剤、薬効剤、油脂類、酸味料、酸化防止剤、着色料、滑沢剤などの従来公知の成分が挙げられる。 The oral care composition of the present invention can be blended with known ingredients generally used in foods, oral care compositions, pharmaceuticals, etc., other than green tea polyphenols and phospholipids, as long as the effects of the present application are not impaired. . For example, conventionally known components such as surfactants, alcohols, water-soluble polymers, flavoring agents (fragrances), sweeteners, medicinal agents, fats and oils, acidulants, antioxidants, coloring agents, lubricants and the like can be mentioned. It is done.
乳化剤としては、非イオン性界面活性剤だけでなく、陰イオン性界面活性剤、および両性界面活性剤を使用することができる。但し、界面活性剤(特に陰イオン性界面活性剤)は、塩化セチルピリジニウムの殺菌作用を低下させる可能性があるため、配合する化学種およびその配合方法、配合量の設計時においては十分な注意を要する。配合できる界面活性剤の例としては以下のものをあげることができる。非イオン性界面活性剤の例としては、ショ糖脂肪酸エステル、マルトース脂肪酸エステル、ラクトース脂肪酸エステル等の糖脂肪酸エステル;ソルビタン脂肪酸エステルやポリオキシエチレンソルビタン脂肪酸エステルなどのソルビタンエステル系界面活性剤;グリセリンモノ脂肪酸エステルやポリオキシエチレングリセリン脂肪酸エステル、ポリグリセリン脂肪酸エステルなどのグリセリン脂肪酸エステル系界面活性剤;ポリオキシエチレンソルビット脂肪酸エステル、ポリエチレンステロール、アルキルグルコシドなどが挙げられる。陰イオン性界面活性剤としては、硫酸エステル系界面活性剤、脂肪酸石鹸、アミノ酸系界面活性剤、リン酸エステル系界面活性剤などが挙げられる。両性界面活性剤としては、アルキルジメチルアミノ酢酸ベタインやアルキルアミドピロピルジメチルアミノ酢酸ベタインなどの酢酸ベタイン型界面活性剤、イミダゾリン型界面活性剤などが挙げられる。これらの界面活性剤は、単独または2種以上を組み合わせて配合することができる。 As the emulsifier, not only a nonionic surfactant but also an anionic surfactant and an amphoteric surfactant can be used. However, since surfactants (especially anionic surfactants) may reduce the bactericidal action of cetylpyridinium chloride, sufficient care must be taken when designing the chemical species to be blended, their blending methods, and blending amounts. Cost. The following can be mentioned as an example of surfactant which can be mix | blended. Examples of nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid ester, maltose fatty acid ester and lactose fatty acid ester; sorbitan ester surfactants such as sorbitan fatty acid ester and polyoxyethylene sorbitan fatty acid ester; glycerin mono Examples include glycerin fatty acid ester surfactants such as fatty acid esters, polyoxyethylene glycerin fatty acid esters, and polyglycerin fatty acid esters; polyoxyethylene sorbit fatty acid esters, polyethylene sterols, and alkyl glucosides. Examples of the anionic surfactant include sulfate ester surfactants, fatty acid soaps, amino acid surfactants, phosphate ester surfactants, and the like. Examples of amphoteric surfactants include betaine acetate type surfactants such as alkyldimethylaminoacetic acid betaines and alkylamidopyropyrudimethylaminoacetic acid betaines, and imidazoline type surfactants. These surfactants can be blended alone or in combination of two or more.
アルコール類としては、エチルアルコール、ブチルアルコール、イソブチルアルコール、プロピルアルコールなどの一価アルコール類、ラクチトール、マンニトール、キシリトールなどの糖アルコール類などが挙げられる。これらのアルコール類は、単独または2種以上を組み合わせて配合することができる。 Examples of alcohols include monohydric alcohols such as ethyl alcohol, butyl alcohol, isobutyl alcohol, and propyl alcohol, and sugar alcohols such as lactitol, mannitol, and xylitol. These alcohols can be blended alone or in combination of two or more.
水溶性高分子としては、例えば、ヒドロキシエチルセルロースやカルボキシメチルセルロース」などのセルロース系水溶性高分子、ペクチンや寒天、カラギーナン、ジェランガムなどの多糖類系高分子、ゼラチンや加水分解コラーゲンペプチドなどのペプチド系高分子などが挙げられる。これらの水溶性高分子は、単独または2種以上を組み合わせて配合することができる。 Examples of water-soluble polymers include cellulose-based water-soluble polymers such as hydroxyethyl cellulose and carboxymethyl cellulose, polysaccharide-based polymers such as pectin, agar, carrageenan, and gellan gum, and peptide-based polymers such as gelatin and hydrolyzed collagen peptides. Examples include molecules. These water-soluble polymers can be blended alone or in combination of two or more.
本発明で用いる香味剤としては、例えば、メントール、アネトール、カルボン、オイゲノール、リモネン、ペパーミントオイル、スペアミントオイル、ウインターグリーン、サリチル酸メチル、シオネール、チモール、丁字油、ユーカリ油、ローズマリー油、セージ油、レモン油、オレンジ油、オシメン油、シトロネロール、メチルオイゲノール等が挙げられる。これらの香味剤は、単独または2種以上を組み合わせて配合することができる。 As the flavoring agent used in the present invention, for example, menthol, anethole, carvone, eugenol, limonene, peppermint oil, spearmint oil, wintergreen, methyl salicylate, shioneer, thymol, clove oil, eucalyptus oil, rosemary oil, sage oil, Lemon oil, orange oil, cymen oil, citronellol, methyl eugenol and the like can be mentioned. These flavoring agents can be blended alone or in combination of two or more.
本発明で用いる甘味料としては、例えば、サッカリンナトリウム、アセスルファームカリウム、ステビオサイド、ネオヘスペリジルジヒドロカルコン、グリチルリチン、ペリラルチン、タウマチン、アスパラチルフェニルアラニルメチルエステル、α−メトキシシンナミックアルデヒド、キシリット、スクロース、スクラロース、パラチノース、パラチニット、エリスリトール、マルチトール等が挙げられる。これらの甘味剤は、単独または2種以上を組み合わせて配合することができる。 Examples of the sweetener used in the present invention include saccharin sodium, acesulfame potassium, stevioside, neohesperidyl dihydrochalcone, glycyrrhizin, perilartine, thaumatin, asparatylphenylalanyl methyl ester, α-methoxycinnamic aldehyde, xylit, sucrose. , Sucralose, palatinose, palatinit, erythritol, maltitol and the like. These sweeteners can be blended alone or in combination of two or more.
緑茶ポリフェノール以外の機能成分も配合することができる。配合できる薬効剤としては、例えば、フッ化ナトリウム、モノフルオロリン酸ナトリウム、フッ化第一錫等のフッ素化合物;デキストラナーゼ、ムタナーゼ、アミラーゼ、プロテアーゼ、溶菌酵素(リテックエンザイム)等の酵素;トラネキサム酸、ε−アミノカプロン酸、アルミニウムクロルヒドロキシアラントイン、アラントイン、ジヒドロコレステロール、グリチルリチン酸類、グリチルレチン酸などの抗炎症剤;塩化セチルピリジニウム、ビサボロール、クロルヘキシジン塩類、トリクロサン、塩化ベンザルコニウム、塩化ベンゼトニウム、イソプロピルメチルフェノールなどの抗菌・殺菌剤;α−トコフェロール、酢酸−dl−α−トコフェロール、ピリドキシン類、アスコルビン酸またはその塩等のビタミン類;グリセロリン酸、クロロフィル、グルコン酸銅、塩化ナトリウム、水溶性無機リン酸化合物、植物抽出物等が挙げられる。これらは、単独で使用しても良く、2種以上を組み合わせて使用しても良い。さらには、緑茶ポリフェノールのようにリポソームに含有させても良いし、オーラルケア組成物の連続層に存在させても良い。 Functional components other than green tea polyphenols can also be blended. Examples of medicinal agents that can be incorporated include fluorine compounds such as sodium fluoride, sodium monofluorophosphate and stannous fluoride; enzymes such as dextranase, mutanase, amylase, protease, and lytic enzyme (Litec Enzyme); tranexam Acid, ε-aminocaproic acid, aluminum chlorohydroxy allantoin, allantoin, dihydrocholesterol, glycyrrhizic acid, glycyrrhetinic acid and other anti-inflammatory agents; cetylpyridinium chloride, bisabolol, chlorhexidine salts, triclosan, benzalkonium chloride, benzethonium chloride, isopropylmethylphenol Antibacterial / bactericidal agents such as α-tocopherol, acetic acid-dl-α-tocopherol, vitamins such as pyridoxine, ascorbic acid or a salt thereof; glycerophosphoric acid, Chlorophyll, copper gluconate, sodium chloride, water-soluble inorganic phosphoric acid compounds, vegetable extracts. These may be used alone or in combination of two or more. Furthermore, you may make it contain in a liposome like green tea polyphenol, and may exist in the continuous layer of an oral care composition.
本発明のオーラルケア組成物は、口腔・咽喉内に適用した場合、存在する唾液と相互作用を生じ、オーラルケア組成物の粘度が著しく高くなることにより、口腔内組織表面や義歯/インプラント表面における組成物の付着・残留量が増加することで、オーラルケア組成物に含まれる有用成分の作用を十分に発揮させることが可能となる。特に、組成物の粘度をできるだけ低くすることで、清掃が不十分になり易い口腔内の峡間部位にまで到達させることが可能となり、口腔衛生環境を著しく向上させることができる。
加えて、組成物の刺激性を大幅に緩和させることから化学物質の刺激に対して敏感な、いわゆる口腔弱者(具体的には、老齢者、口腔内疾患を有する患者、幼若者など)に対しても有用なオーラルケア組成物を提供することができる。
When applied to the oral cavity and throat, the oral care composition of the present invention interacts with existing saliva, and the oral care composition has a significantly high viscosity, so that the oral care composition surface and denture / implant surface By increasing the adhesion / residual amount of the composition, it becomes possible to sufficiently exert the action of useful components contained in the oral care composition. In particular, by making the viscosity of the composition as low as possible, it becomes possible to reach the intraoral site where cleaning is likely to be insufficient, and the oral hygiene environment can be significantly improved.
In addition, for the so-called weak oral people (specifically, elderly people, patients with oral diseases, young people, etc.) who are sensitive to chemical irritation because they greatly reduce the irritation of the composition. Even useful oral care compositions can be provided.
以下、本発明を具体的に説明するが、本発明は下記の例に限定されるものではない。なお、以下特に断りのない限り「%」は「質量%」を示す。 Hereinafter, the present invention will be specifically described, but the present invention is not limited to the following examples. In the following, “%” means “mass%” unless otherwise specified.
リポソーム化カテキン類の増粘作用の評価
(被検体および評価に使用する原料・試薬について)
リン脂質(図表では「リン脂質(*1)」と記載する。)としては、水素添加大豆リン脂質(フォスファチジルコリン含量60質量%以上)を用いた。大豆緑茶ポリフェノール(図表では「緑茶PP(*2)」と記載する。)としては、緑茶ポリフェノール90質量%(内、カテキンガレート類35質量%)を含む粉末を使用した。ルチン、ケルセチン及びヘスペリジンは試薬を使用し、ブドウ種子ポリフェノール(図表では「ブドウ種子PP」と記載する。)はGravinol(キッコーマン(株)社製)を使用した。また、増粘作用の評価には、唾液の代用物として、リン酸緩衝食塩水(PBS(−);リン酸二水素カリウム0.02質量%、塩化カリウム0.02%、リン酸水素二ナトリウム0.115質量%、塩化ナトリウム0.8質量%:図表では「PBS」と記載する。)を用いた。
(被検体の調製方法について)
被検体の製造方法としては、以下の方法に従って行った。
精製水に、表1の「リポソーム製造時配合」欄に包含して記載された各原料を、攪拌しつつ順次投入し、均一にした後、ポータブルミキサー(NGM-0.5TB;美粒社製)を用いて、1000r.p.m.、10分間攪拌することでリポソーム分散液を調製した。
(粘度測定方法について)
得られた各被検体を4.5mlずつ分取し、各々に精製水またはリン酸緩衝食塩水(PBS)を0.5ml添加し、均一になるまで攪拌した。攪拌後、速やかに適量を取り、E型回転粘度計を用いて、20℃、ローター 1゜34‘xR24、回転数1r.p.m.,60秒の条件で粘度を測定した。得られた結果を表1に示す。
Evaluation of thickening action of liposomal catechins
(Subjects and raw materials and reagents used for evaluation)
Hydrogenated soybean phospholipid (phosphatidylcholine content of 60% by mass or more) was used as the phospholipid (described as “phospholipid (* 1)” in the chart). As the soybean green tea polyphenol (described as “green tea PP (* 2)” in the chart), a powder containing 90% by mass of green tea polyphenol (including 35% by mass of catechin gallates) was used. Rutin, quercetin and hesperidin used reagents, and grape seed polyphenol (denoted as “grape seed PP” in the chart) used Gravinol (manufactured by Kikkoman Corp.). In addition, for evaluating the thickening action, as a substitute for saliva, phosphate buffered saline (PBS (-); 0.02% by mass of potassium dihydrogen phosphate, 0.02% of potassium chloride, disodium hydrogen phosphate) 0.115% by mass, sodium chloride 0.8% by mass: described as “PBS” in the chart).
(About sample preparation methods)
The method for producing the specimen was performed according to the following method.
Each raw material included in the column of “Formulation at the time of liposome production” in Table 1 in Purified water is sequentially added while stirring, and after homogenization, a portable mixer (NGM-0.5TB; manufactured by Miki Co., Ltd.) Was used to prepare a liposome dispersion by stirring for 10 minutes at 1000 rpm.
(Viscosity measurement method)
4.5 ml of each of the obtained specimens was collected, 0.5 ml of purified water or phosphate buffered saline (PBS) was added to each, and the mixture was stirred until uniform. After stirring, an appropriate amount was quickly taken, and the viscosity was measured using an E-type rotational viscometer under the conditions of 20 ° C., rotor 1 ° 34 ′ × R24, rotational speed 1 rpm, 60 seconds. The obtained results are shown in Table 1.
表1に示したとおり、緑茶ポリフェノールと水素添加処理した大豆リン脂質を含むリポソームの分散液(実施例1)は、水を添加しても増粘しなかったが、PBSを添加することで、約5.2倍の354mPa・sに増粘した。一方、実施例1より緑茶ポリフェノールを抜いた比較例1においては、PBSを添加しても全く増粘しなかった。また、緑茶ポリフェノールを2倍量に増やしたリポソーム分散液(実施例3)は水添加時の粘度は低くなったにもかかわらずPBS添加時は実施例1の2.5倍の増粘効果を示した。さらに、実施例3のリポソームに流動パラフィンを含有させる(実施例4)と、実施例3と比較し1.4倍の増粘効果を示した。さらに、緑茶ポリフェノールの代わりに、植物由来の代表的なポリフェノールである、ルチン、ケルセチンやフラボノイドであるヘスペリジンを配合したリポソーム分散液についても水、PBS共に全く増粘効果が無かった。なお、ブドウ種子ポリフェノールを配合したリポソーム分散液(比較例5)に関しては、PBS添加時の増粘効果が僅かに確認されたが、実施例の約50%の増粘効果に留まった。以上より、緑茶ポリフェノールと水素添加処理したリン脂質を含むリポソームの分散液は、唾液との相互作用により粘度が大きく増加し、この効果はリポソームに緑茶ポリフェノールを含まない場合や、他のポリフェノール等の場合には確認できなかった。 As shown in Table 1, the dispersion of liposome containing green tea polyphenol and hydrogenated soybean phospholipid (Example 1) did not thicken even when water was added, but by adding PBS, About 5.2 times thickened to 354 mPa · s. On the other hand, in Comparative Example 1 in which green tea polyphenol was removed from Example 1, the viscosity did not increase at all even when PBS was added. In addition, the liposome dispersion (Example 3) in which the amount of green tea polyphenol was doubled was 2.5 times thicker than that of Example 1 when PBS was added, even though the viscosity was low when water was added. Indicated. Furthermore, when the liquid paraffin was contained in the liposome of Example 3 (Example 4), the thickening effect was 1.4 times that of Example 3. Furthermore, a liposome dispersion liquid containing rutin, quercetin, or flavonoid hesperidin, which is a typical plant-derived polyphenol instead of green tea polyphenol, had no thickening effect in both water and PBS. In addition, about the liposome dispersion liquid (comparative example 5) which mix | blended grape seed polyphenol, although the thickening effect at the time of PBS addition was confirmed slightly, it remained at the thickening effect of about 50% of an Example. From the above, the dispersion of liposomes containing green tea polyphenols and hydrogenated phospholipids greatly increases in viscosity due to the interaction with saliva, and this effect can be obtained when the liposomes do not contain green tea polyphenols or other polyphenols. The case could not be confirmed.
以下、本発明に係るオーラルケア組成物の実施例の処方を挙げるが、本発明は下記の処方に限定されるものではない。なお、特に指定の無いかぎり配合量は質量%を示す。 Hereinafter, although the prescription of the Example of the oral care composition concerning the present invention is given, the present invention is not limited to the following prescription. Unless otherwise specified, the blending amount represents mass%.
処方例1(洗口剤)
成 分 配 合 量
チャ抽出物(*1) 0.1
水素添加大豆レシチンA(*2) 1.5
濃グリセリン 10
プロピレングリコール 5
クエン酸 0.01
クエン酸3ナトリウム 0.1
パラオキシ安息香酸メチル 0.1
サッカリンナトリウム 0.02
香料 0.05
精製水 残 部
合 計 100
*1 ポリフェノン70A(三井農林(株)社製)
*2 SLP−PC70HS(辻製油(株)社製):リン脂質全量に対してホスファチジルコリン含有量が70質量%以上
(製造方法)
仕掛としてチャ抽出物、水素添加レシチン、香料をプロピレングリコールに添加し、70℃まで加温して溶解し、10%の精製水に添加した後に、高圧乳化機により均一に攪拌することでリポソーム懸濁液を調製する。別途残部の精製水及びその他の成分を混合し、可溶化した混合液に前記リポソーム懸濁液を添加し、均一になるまで混合攪拌する。
Formulation Example 1 (Mouthwash)
Component amount
Tea extract (* 1) 0.1
Hydrogenated soybean lecithin A (* 2) 1.5
Concentrated glycerin 10
Propylene glycol 5
Citric acid 0.01
Trisodium citrate 0.1
Methyl paraoxybenzoate 0.1
Saccharin sodium 0.02
Fragrance 0.05
Purified water balance
Total 100
* 1 Polyphenon 70A (Mitsui Norin Co., Ltd.)
* 2 SLP-PC70HS (manufactured by Sakai Oil Co., Ltd.): The phosphatidylcholine content is 70% by mass or more based on the total amount of phospholipid.
(Production method)
As a mechanism, tea extract, hydrogenated lecithin, and fragrance are added to propylene glycol, heated to 70 ° C. to dissolve, added to 10% purified water, and then uniformly stirred by a high-pressure emulsifier to suspend liposomes. Prepare a suspension. Separately, the remaining purified water and other components are mixed, and the liposome suspension is added to the solubilized mixture, followed by mixing and stirring until uniform.
処方例2(洗口剤)
成 分 配 合 量
緑茶抽出物(*3) 0.1
水素添加大豆レシチンB(*4) 1
濃グリセリン 10
プロピレングリコール 5
キシリトール 2
水酸化ナトリウム 0.2
エデト酸二ナトリウム 0.05
パラオキシ安息香酸メチル 0.1
グリチルリチン酸ジカリウム 0.05
炭酸水素ナトリウム 0.03
サッカリンナトリウム 0.01
香料 0.1
精製水 残 部
合 計 100
*3 ティアカロン90((株)常磐植物研究所社製)
*4 COATSOME NC−21(日油(株)社製):リン脂質全量に対してホスファチジルコリン含有量が90質量%以上
(製造方法)
仕掛として緑茶抽出物、水素添加レシチン、香料をプロピレングリコールに添加し、70℃まで加温して溶解し、10%の精製水に添加した後に、高圧乳化機により均一に攪拌することでリポソーム懸濁液を調製する。別途残部の精製水及びその他の成分を混合し、可溶化した混合液に前記リポソーム懸濁液を添加し、均一になるまで混合攪拌する。
Formulation Example 2 (Mouthwash)
Component amount
Green tea extract (* 3) 0.1
Hydrogenated soybean lecithin B (* 4) 1
Concentrated glycerin 10
Propylene glycol 5
Xylitol 2
Sodium hydroxide 0.2
Edetate disodium 0.05
Methyl paraoxybenzoate 0.1
Dipotassium glycyrrhizinate 0.05
Sodium bicarbonate 0.03
Saccharin sodium 0.01
Fragrance 0.1
Purified water balance
Total 100
* 3 Teacalon 90 (manufactured by Joban Plant Research Institute)
* 4 COATSOME NC-21 (manufactured by NOF Corporation): The phosphatidylcholine content is 90% by mass or more based on the total amount of phospholipid.
(Production method)
As a mechanism, green tea extract, hydrogenated lecithin, and fragrance are added to propylene glycol, heated to 70 ° C. to dissolve, added to 10% purified water, and then uniformly stirred by a high-pressure emulsifier. Prepare a suspension. Separately, the remaining purified water and other components are mixed, and the liposome suspension is added to the solubilized mixture, followed by mixing and stirring until uniform.
処方例3(保湿洗口剤)
成 分 配 合 量
緑茶抽出物(*5) 0.05
水素添加大豆レシチンC(*6) 0.8
濃グリセリン 10
プロピレングリコール 5
ヒアルロン酸ナトリウム 0.3
トレハロース 0.2
パラオキシ安息香酸メチル 0.1
クエン酸 0.01
クエン酸3ナトリウム 0.1
サッカリンナトリウム 0.02
香料 0.05
精製水 残 部
合 計 100
*5 サンフェノンEGCG−OP(太陽化学(株)社製)
*6 PHOSPHOLIPON 90H(Lipoid社製):リン脂質全量に対してホスファチジルコリン含有量が90質量%以上
(製造方法)
仕掛として緑茶抽出物、水素添加レシチン、香料をプロピレングリコールに添加し、70℃まで加温して溶解し、10%の精製水に添加した後に、高圧乳化機により均一に攪拌することでリポソーム懸濁液を調製する。別途残部の精製水にアルギン酸ナトリウムを均一溶解したのちに前記リポソーム懸濁液およびその他の成分を順次添加し、均一になるまで減圧条件下で混合攪拌する。
Formulation Example 3 (Moisturizing mouthwash)
Component amount
Green tea extract (* 5) 0.05
Hydrogenated soybean lecithin C (* 6) 0.8
Concentrated glycerin 10
Propylene glycol 5
Sodium hyaluronate 0.3
Trehalose 0.2
Methyl paraoxybenzoate 0.1
Citric acid 0.01
Trisodium citrate 0.1
Saccharin sodium 0.02
Fragrance 0.05
Purified water balance
Total 100
* 5 Sanphenon EGCG-OP (manufactured by Taiyo Chemical Co., Ltd.)
* 6 PHOSPHOLIPON 90H (manufactured by Lipoid): The phosphatidylcholine content is 90% by mass or more with respect to the total amount of phospholipid.
(Production method)
As a mechanism, green tea extract, hydrogenated lecithin, and fragrance are added to propylene glycol, heated to 70 ° C. to dissolve, added to 10% purified water, and then uniformly stirred by a high-pressure emulsifier. Prepare a suspension. Separately, after dissolving sodium alginate uniformly in the remaining purified water, the liposome suspension and other components are sequentially added, and mixed and stirred under reduced pressure until uniform.
処方例4(口腔・咽喉用噴霧剤)
成 分 配 合 量
塩化セチルピリジニウム 150mg
チャ抽出物(*7) 15mg
水素添加大豆レシチンE(*8)1500mg
プロピレングリコール 1000mg
グリセリン 5000mg
果糖ぶどう糖液糖 1000mg
クエン酸 800mg
クエン酸ナトリウム 400mg
安息香酸ナトリウム 500mg
スクラロース 50mg
白金ナノコロイド 2mg
香料 250mg
精製水 残 部
合 計 50g
*7 ピュアフェノン50W(小川香料(株)社製)
*8 SLP−PC92(辻製油(株)社製):リン脂質全量に対してホスファチジルコリン含有量が90質量%以上
(製造方法)
仕掛として塩化セチルピリジニウム、チャ抽出物、水素添加レシチン、香料をプロピレングリコールに添加し、70℃まで加温して溶解し、精製水に高圧乳化機の攪拌下で少量ずつ添加し、均一に攪拌しリポソーム懸濁液を調製する。その後、その他の成分を順次添加、混合し、均一になるまで混合攪拌する。
Formulation Example 4 (Oral / Throat Spray)
Component amount
Cetylpyridinium chloride 150mg
Cha extract (* 7) 15mg
Hydrogenated soybean lecithin E (* 8) 1500mg
Propylene glycol 1000mg
Glycerin 5000mg
Fructose glucose liquid sugar 1000mg
Citric acid 800mg
Sodium citrate 400mg
Sodium benzoate 500mg
Sucralose 50mg
Platinum nanocolloid 2mg
Fragrance 250mg
Purified water balance part Total 50g
* 7 Purephenon 50W (Ogawa Fragrance Co., Ltd.)
* 8 SLP-PC92 (manufactured by Sakai Oil Co., Ltd.): The phosphatidylcholine content is 90% by mass or more based on the total amount of phospholipid.
(Production method)
Add cetylpyridinium chloride, tea extract, hydrogenated lecithin, and fragrance to propylene glycol as a mechanism, heat to 70 ° C to dissolve, add to purified water little by little under high-pressure emulsifier stirring, and stir uniformly Liposome suspension is prepared. Thereafter, the other components are added and mixed sequentially, and mixed and stirred until uniform.
処方例5(洗口剤)
成 分 配 合 量
塩化セチルピリジニウム 0.1
チャ抽出物(*9) 0.1
水素添加卵黄レシチンA(*10) 2.5
濃グリセリン 10
プロピレングリコール 5
パラオキシ安息香酸メチル 0.1
クエン酸 0.01
クエン酸3ナトリウム 0.1
サッカリンナトリウム 0.02
香料 0.05
精製水 残 部
合 計 100
*9 ポリフェノンG(三井農林(株)社製)
*10 卵黄レシチンPL−100P(キューピー(株)社製):リン脂質全量に対してホスファチジルコリン含有量が80質量%以上
(製造方法)
仕掛として塩化セチルピリジニウム、チャ抽出物、水素添加レシチン、香料をプロピレングリコールに添加し、70℃まで加温して溶解し、5%の精製水に添加した後に、高圧乳化機により均一に攪拌することでリポソーム懸濁液を調製する。別途残部の精製水及びその他の成分を混合し、可溶化した混合液に前記リポソーム懸濁液を添加し、均一になるまで混合攪拌する。
Formulation Example 5 (Mouthwash)
Component amount
Cetylpyridinium chloride 0.1
Tea extract (* 9) 0.1
Hydrogenated egg yolk lecithin A (* 10) 2.5
Concentrated glycerin 10
Propylene glycol 5
Methyl paraoxybenzoate 0.1
Citric acid 0.01
Trisodium citrate 0.1
Saccharin sodium 0.02
Fragrance 0.05
Purified water balance
Total 100
* 9 Polyphenon G (Mitsui Norin Co., Ltd.)
* 10 Egg yolk lecithin PL-100P (manufactured by Kewpie Co., Ltd.): phosphatidylcholine content is 80% by mass or more based on the total amount of phospholipids
(Production method)
Add cetylpyridinium chloride, tea extract, hydrogenated lecithin, and fragrance to propylene glycol as a mechanism, heat to 70 ° C to dissolve, add to 5% purified water, and then stir uniformly with high-pressure emulsifier To prepare a liposome suspension. Separately, the remaining purified water and other components are mixed, and the liposome suspension is added to the solubilized mixture, followed by mixing and stirring until uniform.
処方例6(ポンプスプレイ用口腔・咽喉用殺菌塗布剤)
成 分 配 合 量
緑茶抽出物(*11) 0.2
水素添加大豆レシチンG(*12) 2
濃グリセリン 10
ソルビトール 10
プロピレングリコール 5
エチルアルコール 3
クエン酸 0.1
クエン酸ナトリウム 0.01
香料 0.2
精製水 残 部
合 計 100
*11 ティアカロン30((株)常磐植物研究所社製)
*12 ベイシス LS−60HR(日清オイリオグループ(株)社製):リン脂質全量に対してホスファチジルコリン含有量が65質量%以上
(製造方法)
仕掛として緑茶抽出物、水素添加レシチン、香料をプロピレングリコールに添加し、70℃まで加温して均一溶解したものを精製水に添加し、高圧乳化機により均一に攪拌し、リポソーム懸濁液を調製する。別途、クエン酸とクエン酸3ナトリウムを少量の精製水に溶解しておき、該リポソーム懸濁液に残部の精製水を順次攪拌しつつ投入したのちに、ソルビトール、クエン酸等の溶解液、グリセリン及びエチルアルコールに溶解した香料を順次添加し、均一になるまで混合攪拌する。
Formulation Example 6 (Sterile application for oral cavity and throat for pump spray)
Component amount
Green tea extract (* 11) 0.2
Hydrogenated soybean lecithin G (* 12) 2
Concentrated glycerin 10
Sorbitol 10
Propylene glycol 5
Ethyl alcohol 3
Citric acid 0.1
Sodium citrate 0.01
Fragrance 0.2
Purified water balance section Total 100
* 11 Tea Calon 30 (manufactured by Tokiwa Plant Research Institute)
* 12 Basis LS-60HR (manufactured by Nisshin Oillio Group Co., Ltd.): The phosphatidylcholine content is 65% by mass or more based on the total amount of phospholipids.
(Production method)
Add the green tea extract, hydrogenated lecithin, and fragrance to propylene glycol as a mechanism, heat up to 70 ° C and dissolve uniformly, add to purified water, and stir uniformly with a high-pressure emulsifier. Prepare. Separately, citric acid and trisodium citrate are dissolved in a small amount of purified water, and the remaining purified water is added to the liposome suspension while sequentially stirring, and then a solution of sorbitol, citric acid, etc., glycerin And the fragrance | flavor melt | dissolved in ethyl alcohol is added in order, and it mixes and stirs until it becomes uniform.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014068015A JP6486601B2 (en) | 2014-03-28 | 2014-03-28 | Oral care composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014068015A JP6486601B2 (en) | 2014-03-28 | 2014-03-28 | Oral care composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015189708A true JP2015189708A (en) | 2015-11-02 |
JP6486601B2 JP6486601B2 (en) | 2019-03-20 |
Family
ID=54424532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014068015A Active JP6486601B2 (en) | 2014-03-28 | 2014-03-28 | Oral care composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6486601B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018062492A1 (en) * | 2016-09-29 | 2018-04-05 | ライオン株式会社 | Aerosol for interdental cleaning |
JP2022535943A (en) * | 2019-06-14 | 2022-08-10 | ザ プロクター アンド ギャンブル カンパニー | Leave-in oral care composition |
US11883520B2 (en) | 2019-06-14 | 2024-01-30 | The Procter & Gamble Company | Leave-on oral care compositions |
US11904041B2 (en) | 2019-06-14 | 2024-02-20 | The Procter & Gamble Company | Leave-on oral care compositions |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6351311A (en) * | 1986-08-20 | 1988-03-04 | Kobayashi Kooc:Kk | Skin cosmetic |
JPH0656687A (en) * | 1992-08-04 | 1994-03-01 | Itouen:Kk | Scaling agent and preventing agent for deposition of dental calculus |
JP2003119120A (en) * | 2001-10-12 | 2003-04-23 | Masahiko Abe | Method for producing liposome, cosmetic containing the liposome, and skin care preparation |
JP2005536481A (en) * | 2002-06-21 | 2005-12-02 | ピードモント ファーマシューティカルズ エルエルシー | Liposomes containing biologically active substances |
JP2007223975A (en) * | 2006-02-24 | 2007-09-06 | Sunstar Inc | Composition for oral cavity, containing lactoferrin-encapsulating liposome |
JP2009196987A (en) * | 2008-01-23 | 2009-09-03 | Kao Corp | Tooth paste composition for periodontal disease |
JP2010064961A (en) * | 2008-09-09 | 2010-03-25 | Meiji Milk Prod Co Ltd | Agent for adjusting normal oral bacterial flora and method for adjusting normal oral bacterial flora using the same |
JP2012051872A (en) * | 2010-08-05 | 2012-03-15 | Shiseido Co Ltd | Skin cosmetic |
JP2012508009A (en) * | 2008-11-07 | 2012-04-05 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | Novel polyaminopolyketide antibiotics and uses thereof |
JP2012171879A (en) * | 2011-02-18 | 2012-09-10 | Nippon Medical School | Oral composition |
JP2013506644A (en) * | 2009-10-01 | 2013-02-28 | ロレアル | Use of vanillin derivatives as preservatives, storage methods, compounds, and compositions |
JP2013136544A (en) * | 2011-12-28 | 2013-07-11 | Kao Corp | Gelled skin care preparation |
-
2014
- 2014-03-28 JP JP2014068015A patent/JP6486601B2/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6351311A (en) * | 1986-08-20 | 1988-03-04 | Kobayashi Kooc:Kk | Skin cosmetic |
JPH0656687A (en) * | 1992-08-04 | 1994-03-01 | Itouen:Kk | Scaling agent and preventing agent for deposition of dental calculus |
JP2003119120A (en) * | 2001-10-12 | 2003-04-23 | Masahiko Abe | Method for producing liposome, cosmetic containing the liposome, and skin care preparation |
JP2005536481A (en) * | 2002-06-21 | 2005-12-02 | ピードモント ファーマシューティカルズ エルエルシー | Liposomes containing biologically active substances |
JP2007223975A (en) * | 2006-02-24 | 2007-09-06 | Sunstar Inc | Composition for oral cavity, containing lactoferrin-encapsulating liposome |
JP2009196987A (en) * | 2008-01-23 | 2009-09-03 | Kao Corp | Tooth paste composition for periodontal disease |
JP2010064961A (en) * | 2008-09-09 | 2010-03-25 | Meiji Milk Prod Co Ltd | Agent for adjusting normal oral bacterial flora and method for adjusting normal oral bacterial flora using the same |
JP2012508009A (en) * | 2008-11-07 | 2012-04-05 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | Novel polyaminopolyketide antibiotics and uses thereof |
JP2013506644A (en) * | 2009-10-01 | 2013-02-28 | ロレアル | Use of vanillin derivatives as preservatives, storage methods, compounds, and compositions |
JP2012051872A (en) * | 2010-08-05 | 2012-03-15 | Shiseido Co Ltd | Skin cosmetic |
JP2012171879A (en) * | 2011-02-18 | 2012-09-10 | Nippon Medical School | Oral composition |
JP2013136544A (en) * | 2011-12-28 | 2013-07-11 | Kao Corp | Gelled skin care preparation |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018062492A1 (en) * | 2016-09-29 | 2018-04-05 | ライオン株式会社 | Aerosol for interdental cleaning |
JP2022535943A (en) * | 2019-06-14 | 2022-08-10 | ザ プロクター アンド ギャンブル カンパニー | Leave-in oral care composition |
JP7288090B2 (en) | 2019-06-14 | 2023-06-06 | ザ プロクター アンド ギャンブル カンパニー | Leave-in oral care composition |
US11883368B2 (en) | 2019-06-14 | 2024-01-30 | The Procter & Gamble Company | Leave-on oral care compositions |
US11883520B2 (en) | 2019-06-14 | 2024-01-30 | The Procter & Gamble Company | Leave-on oral care compositions |
US11904041B2 (en) | 2019-06-14 | 2024-02-20 | The Procter & Gamble Company | Leave-on oral care compositions |
Also Published As
Publication number | Publication date |
---|---|
JP6486601B2 (en) | 2019-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11890361B2 (en) | Oral care composition comprising cannabinoids | |
JP6077149B2 (en) | Dentifrice composition for periodontal disease | |
TWI438006B (en) | Oral compositions comprising propolis | |
CN104870179B (en) | Buffer microcapsule composition and method | |
JP5665888B2 (en) | Oral care composition | |
JP2015212274A (en) | Oral care composition | |
JP2016517445A (en) | Polyphenol / flavonoid composition and method for formulating oral hygiene products | |
JP6486601B2 (en) | Oral care composition | |
JP5932786B2 (en) | Composition for prevention of candidiasis | |
JP2007308443A (en) | Cataplasm product for oral cavity | |
JP4875381B2 (en) | Oral composition containing lactoferrin-encapsulating liposomes | |
JP6440954B2 (en) | Oral care composition | |
KR20200139175A (en) | Buffered microencapsulation composition and method | |
JP6471407B2 (en) | Oral or throat composition | |
JP5382052B2 (en) | Bad breath odor suppressor and oral composition for suppressing bad breath | |
JP6580735B2 (en) | Oral care composition | |
CN104606085B (en) | A kind of chlorhexidine acetate nano-emulsion gargle of antibacterial and preparation method thereof | |
JP2021017450A (en) | Compositions and methods for treating oral cavity | |
JP5197707B2 (en) | Anti-endotoxin agent and composition for oral cavity containing periodontal disease containing the same | |
JP4721630B2 (en) | Anti-endotoxin agent and composition for oral cavity containing periodontal disease containing the same | |
Arif et al. | Progression in Nano-Botanical Oral Hygiene Solutions: The Dawn of Biomimetic Nanomaterials | |
CN105616177B (en) | A kind of nanoparticle with tooth target function and preparation method thereof and oral care product | |
JP6339504B2 (en) | New composition | |
JP6848021B2 (en) | Oral composition for suppressing the generation of methyl mercaptan | |
Sriram et al. | Effectiveness of green tea on oral health in children. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170308 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180116 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20180119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180305 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180508 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181205 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20181212 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190122 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190220 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6486601 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |